## CORRECTION Open Access

## Correction: Extracellular matrix remodeling proteins as biomarkers for clinical assessment and treatment outcomes in eosinophilic esophagitis

Martin Pehrsson<sup>1†</sup>, Willemijn E. de Rooij<sup>2\*†</sup>, Anne-Christine Bay-Jensen<sup>1</sup>, Morten Asser Karsdal<sup>1</sup>, Joachim Høg Mortensen<sup>1</sup> and Albert Jan Bredenoord<sup>2</sup>

Correction: BMC Gastroenterol 23, 357 (2023) https://doi.org/10.1186/s12876-023-02977-z

Following publication of the original article [1] it was reported that Figs. 1, 2, 3 and 4 were either missing asterisks indicating statistical significance, or the asterisks were incorrectly replaced with a '1'.

The affected figure panels were the following:

- Fig. 1A, C, F, G, H, I, K, and L
- Fig. 2A-D
- Fig. 3
- Fig. 4D

The updated figures are included in this Correction article and the original article has been updated.

Published online: 22 November 2023

## Reference

 Pehrsson M, de Rooij WE, Bay-Jensen AC, et al. Extracellular matrix remodeling proteins as biomarkers for clinical assessment and treatment outcomes in eosinophilic esophagitis. BMC Gastroenterol. 2023;23:357. https://doi.org/10.1186/s12876-023-02977-z.

The original article can be found online at https://doi.org/10.1186/s12876-023-02977-z.

\*Correspondence:

Willemijn E. de Rooij

w.e.derooij@amsterdamumc.nl


<sup>&</sup>lt;sup>2</sup> Department of Gastroenterology & Hepatology, Amsterdam University Medical Center, Amsterdam, Netherlands




© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you rintended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>&</sup>lt;sup>†</sup>Martin Pehrsson and Willemijn E. de Rooij contributed equally to this work.

<sup>&</sup>lt;sup>1</sup> Biomarkers and Research, Nordic Bioscience A/S, Herley, Denmark




**Fig. 1** Blood-based biomarkers reflecting extracellular matrix remodeling and immune-cell activity in healthy controls and patients with EoE. The mean with standard deviation serum levels of PRO-C3 (**A**), CTX-III (**B**), C3M (**C**), PC3X (**D**), PRO-C4 (**E**), C4M (**F**), PRO-C5 (**G**), PRO-C6 (**H**), C6M (**I**), VICM (**J**), VIM (**K**), and Cpa9-HNE (**L**) were plotted for the individual patients of a group of age- and gender-matched healthy controls and patients with eosinophilic esophagitis (EoE) at baseline and after the intervention. The mean biomarker levels of patients with EoE were compared to the healthy controls using one-way ANOVA Kruskal–Wallis and applying Dunn's test to correct for multiple comparisons. The statistical difference was calculated by unpaired t-test or Mann–Whitney, with significance as  $p < 0.05^*$ ,  $p < 0.01^{***}$ ,  $p < 0.001^{****}$ , and  $p < 0.0001^{****}$ 




**Fig. 2** Endoscopically assessed endotypes and fibrosis changes associated with an altered interstitial matrix remodeling. Baseline and after-intervention serum CTX-III ( $\bf A$ ) and net cross-linked fibrolysis (CTX-III mean levels divided by PRO-C3 mean levels) ( $\bf B$ ) of patients with a *severe fibrotic endotype'* (EREFS fibrotic subscore 2–4; n = 20) or a 'mild fibrotic endotype' (EREFS fibrotic subscore 0–1; n = 9). The plotted baseline and after-intervention levels of PRO-C3 ( $\bf C$ ) and PRO-C6 ( $\bf D$ ) for patients with a 'regressive' (decreased EREFS fibrotic subscore; n = 14) or 'progressive' (increased EREFS fibrotic subscore, n = 12) fibrotic endotype. Error bars represent standard errors of the mean (SEM). The statistical difference was calculated by unpaired t-test or Mann–Whitney, with significance as p < 0.05 \*, p < 0.01\*\*

## **CPa9-HNE**NEUTROPHILIC ACTIVITY BY HUMAN NEUTROPHIL ELASTASE DEGRADED CALPROTECTIN



Endoscopic inflammation (EREFS) after intervention

**Fig. 3** Neutrophil activity elevated with increased disease activity. Baseline biomarker levels of CPa9-HNE are plotted for patients with an EREFS inflammatory subscore of 0–1 ('mild inflammatory endotype'; n = 11) and 2–3 ('severe inflammatory endotype'; n = 17) after-intervention (**A**). The statistical difference was calculated by Mann–Whitney, with significance as p < 0.05\*



**Fig. 4** Non-invasive extracellular matrix remodeling biomarkers are associated with histological remission and regression of food impaction. CTX-III levels (**A**) and net fibrolysis (CTX-III mean levels divided by PRO-C3 mean levels) (**B**) were plotted for after-intervention 'histological remission' (peak eosinophilic count < 15/hpf; n = 10) or 'no histological remission' (peak eosinophilic count  $\ge 15$ /hpf; n = 19). Biomarker levels of C3M (**C**) and net type IV collagen degradation (C4M mean levels divided by PRO-C4 mean levels) (**D**) for patients presenting with 'no food impaction' (n = 10) or 'food impaction' (n = 6) after intervention. Error bars represent standard errors of the mean (SEM). The statistical differences in biomarker levels were calculated by unpaired t-test or Mann–Whitney, with significance as p < 0.05\*